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Abstract 25 
Dendritic cells (DCs) are potent antigen presenting cells, described as the initiators of 26 
adaptive immune responses. Immature monocyte-derived DCs (MDDC) showed decreased 27 
CD14 expression, increased cell surface markers DC-SIGN and CD1a and enhanced levels of 28 
receptors for the chemokines CCL3 (CCR1/CCR5) and CXCL8 (CXCR1/CXCR2) compared 29 
with human CD14+ monocytes. After further MDDC maturation by LPS, the markers CD80 30 
and CD83 and the chemokine receptors CXCR4 and CCR7 were upregulated, whereas CCR1, 31 
CCR2 and CCR5 expression was reduced. CCL3 dose-dependently synergized with CXCL8 32 
or CXCL12 in chemotaxis of immature MDDC. CXCL12 augmented the CCL3-induced 33 
ERK1/2 and Akt phosphorylation in immature MDDC, although the synergy between CCL3 34 
and CXCL12 in chemotaxis of immature MDDC was dependent on the Akt signaling pathway 35 
but not on ERK1/2 phosphorylation. CCL2 also synergized with CXCL12 in immature 36 
MDDC migration. Moreover, two CXC chemokines not sharing receptors (CXCL12 and 37 
CXCL8) cooperated in immature MDDC chemotaxis, whereas two CC chemokines (CCL3 38 
and CCL7) sharing CCR1 did not. Further, the non-chemokine G protein-coupled receptor 39 
ligands chemerin and fMLP synergized with respectively CCL7 and CCL3 in immature 40 
MDDC signaling and migration. Finally, CXCL12 and CCL3 did not cooperate, but CXCL12 41 
synergized with CCL21 in mature MDDC chemotaxis. Thus, chemokine synergy in immature 42 
and mature MDDC migration is dose-dependently regulated by chemokines via alterations in 43 
their chemokine receptor expression pattern according to their role in immune responses. 44 
 45 
 46 
 47 
 48 
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Introduction 49 
Chemokines are crucially involved in inflammatory responses via their capacity to recruit 50 
selective leukocyte subsets (Bonecchi et al., 2009; Raman et al., 2011). Leukocyte migration 51 
is dependent on the expression of cell-adhesion molecules (CAMs), such as selectins and 52 
integrins, which provide the driving force for leukocyte interaction with endothelial cells. 53 
Chemokine binding to extracellular matrix and chemokine receptors allow the cells to migrate 54 
along chemotactic gradients (Murphy et al., 2000; Rot and von Andrian, 2004). However, 55 
chemokine biology is more intricate than simple ligand-receptor interaction, as several studies 56 
suggest that chemokines can form dimers (Fernando et al., 2004), also after binding to 57 
glycosaminoglycans (GAG) on endothelial cells, and their receptors are found as dimers 58 
and/or oligomers at the cell surface (Johnson et al., 2005; Springael et al., 2005; Thelen et al., 59 
2010). Moreover, multiple chemokines secreted within inflamed loci selectively enhance each 60 
other’s migratory functions on leukocytes, depending on their concentration, proximity and 61 
production kinetics (Gouwy et al., 2012). Indeed, our previous findings demonstrate that at a 62 
suboptimal concentration, the CC chemokine CCL2 synergizes with the CXC chemokine 63 
CXCL8 to chemoattract monocytes (Gouwy et al., 2008). CCL3, CCL5 and CCL8, three 64 
potent mononuclear cell chemoattractants, are also able to synergize with the homeostatic 65 
chemokine CXCL12 in the migration of CD14+ monocytes, CD3+ T-lymphocytes or PHA-66 
activated lymphoblasts (Gouwy et al., 2011). Similarly, homeostatic CCL19 and CCL21 were 67 
reported to enhance CCL7-induced monocyte migration (Kuscher et al., 2009).   68 
The main function of dendritic cells (DCs) is to process and present antigens, via MHC 69 
molecules on the cell surface, to T cells of the immune system. Once activated by antigen, the 70 
immature dendritic cells in the blood or tissues migrate into lymph nodes and spleen where 71 
they act as antigen presenting cells and activate T and B cells to initiate the adaptive immune 72 
responses (Allavena et al., 2000; Banchereau et al., 2000; Sallusto and Lanzavecchia, 1999; 73 
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Steinman et al., 2003). DCs also play major roles in pathological processes including 74 
autoimmune diseases, graft rejection and human immunodeficiency virus infection (Cameron 75 
et al., 1992; Larsen et al., 1990; Steinman RM, 2003).  76 
The chemotactic migratory properties of DCs in response to specific chemokines are strictly 77 
regulated during their development from progenitor cells. These regulatory mechanisms are 78 
implicated in mediating the trafficking of DC from blood to tissues and then to lymph nodes 79 
(Dieu et al., 1998; Sato et al., 1999; Sozzani et al., 1998; Sozzani et al., 1999). Migration of 80 
DC into tissues depends on a cascade of discrete events, including chemokine production and 81 
regulation of chemokine receptor expression.  82 
In this study, we investigated the synergy between chemoattractants in immature and mature 83 
MDDC chemotaxis. In particular, we compared the synergy between CXC (i.e. CXCL8 or 84 
CXCL12) and CC (i.e. CCL2, CCL3 or CCL7) chemokines in immature MDDC as well as 85 
the cooperation between non-chemokine G protein-coupled receptor (GPCR) ligands (i.e. 86 
fMLP or chemerin) and chemokines to chemoattract immature MDDC. Moreover, the 87 
cooperation between CC (i.e. CCL3 or CCL21) and CXC (e.g. CXCL12) chemokines was 88 
tested after maturation of MDDC. Due to the complexity of the chemokine binding and 89 
signaling system several mechanisms have been proposed to provide an explanation for the 90 
synergy between chemokines in leukocyte migration (Gouwy et al., 2012). For instance, 91 
chemokine amplification of inflammatory responses could be mediated through the 92 
synergistic interplay of distinct signaling pathways downstream of GPCR activation (Gouwy 93 
et al., 2011). To examine the pathways involved in the synergy between CXCL12 and CCL3 94 
in immature MDDC migration, cells were treated with inhibitors of signal transduction. Our 95 
findings show that expression levels of chemokines and chemokine receptors regulate the 96 
synergy between chemokines in chemotaxis of immature MDDC, linking the innate and 97 
adaptive immune responses. 98 
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Materials and methods 99 
Reagents 100 
Recombinant human CCL3, CCL21 and chemerin(21-157) were obtained from R&D Systems 101 
(Minneapolis, MN). Recombinant human CXCL8(6-77) was purchased from Peprotech 102 
(Rocky Hill, NJ). The bacterial chemotactic peptide fMLP and the CXCR4 antagonist 103 
AMD3100 were from Sigma (St. Louis, MO). Synthetic intact CXCL12 and CCL7 were 104 
synthesized by solid-phase peptide synthesis using fluorenylmethoxycarbonyl (Fmoc) 105 
chemistry and were purified as described previously (Gouwy et al., 2011). Natural CCL2 was 106 
purified to homogeneity from monocyte-derived conditioned medium (Gouwy et al., 2008).  107 
 108 
Cells 109 
Blood was collected upon heparin, and PBMCs were seperated from granulocytes and 110 
erythrocytes by density gradient centrifugation (400g, 30 min, 15 °C) on Ficoll-sodium 111 
diatrizoate (Lymphoprep; Invitrogen, Groningen, The Netherlands). CD14+ monocytes were 112 
isolated by MACS following the manufacturer’s instructions (Miltenyi Biotec, Bergisch 113 
Gladbach, Germany). A purity of 99% was obtained for CD14+ monocytes as determined by 114 
flow cytometry. Immature MDDC were generated by incubating purified peripheral blood 115 
CD14+ monocytes in plastic tissue culture dishes (10 ml/dish; 100x20 mm; 55 cm²; 116 
International Medical products) at 1x106 cells/ml in RPMI medium containing 10% FCS 117 
(Hyclone, Cramlington, UK), 50 ng/ml GM-CSF (Prospec, East Brunswick, NY) and 20 118 
ng/ml IL-4 (Prospec) at 37°C in a CO2 (5%) incubator for 6 days. Subsequently, for 119 
maturation, dendritic cells were incubated in fresh RPMI medium with 10% FCS containing 1 120 
µg/ml LPS (Alexis Biochemicals, Enzo Life Science, NY, USA) for 48 h (37°C, 5% CO2). 121 
No specific approval from an institutional review board is required for the use of buffy coats 122 
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for the following reasons: (1) no personal patient information is made available, (2) buffy 123 
coats cannot be used for treatment of patients and are therefore waste products for the blood 124 
transfusion centre and (3) blood donors sign an agreement that parts of the donation that 125 
cannot be used for patient treatment may be used for scientific research. 126 
 127 
Flow cytometry analysis 128 
The expression of surface molecules and chemokine receptors on CD14+ monocytes, 129 
immature and mature MDDC was analysed by flow cytometry. Cells were collected and 130 
incubated for 10 min at 4°C with ice-cold FACS buffer (PBS supplemented with 2% FCS) 131 
and Fc block to prevent aspecific binding of the antibodies. For direct staining, cells (0.3x106 132 
cells) were subsequently incubated for 30 min on ice with phycoerythrin (PE)-labeled 133 
monoclonal antibodies recognizing CCR7 (clone 150503; R&D Systems), CD80 (clone 134 
L307.4; Becton Dickinson, San Jose, CA), CD86 (clone 2331) or CD14 (clone M5E2) (BD 135 
Pharmingen, Heidelberg, Germany), fluorescein (FITC)-labeled monoclonal antibodies 136 
recognizing DC-SIGN (clone DCN46; BD Pharmingen) or CD83 (clone HB15e; Biolegend, 137 
San Diego, CA) and allophycocyanin (APC)-labeled monoclonal antibodies recognizing 138 
CD11b (clone ICRF44; BD Pharmingen) or CD1a (clone HI149; Biolegend). Cell 139 
preparations with the corresponding FITC-, PE- (BD Pharmingen) or APC-conjugated 140 
(eBioscience, San Diego, CA) isotype-matched control monoclonal antibodies were also 141 
prepared. For indirect staining, the cells were incubated with mouse anti-CXCR1 (clone 142 
5A12), anti-CXCR2 (clone 6C6) and anti-CXCR4 monoclonal antibody (clone 12G5; BD 143 
Pharmingen), anti-CCR1 (clone 53504), anti-CCR2 (clone 48607) and anti-CCR5 (clone 144 
45531) monoclonal antibody (R&D Systems) for 30 min on ice, washed twice with FACS 145 
buffer and subsequently stained (30 min on ice) with PE-conjugated goat anti-mouse IgG 146 
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polyclonal antibody (BD Pharmingen). Thereafter, the cells were washed twice and fixed with 147 
4% formaldehyde in FACS buffer. Analysis of fluorescence was performed with a 148 
FACSCalibur flow cytometer (Becton Dickinson) and CellQuest Software. The expression 149 
level of the markers and chemokine receptors between monocytes, immature and mature 150 
MDDC was compared and the corresponding p value was calculated with the Mann-Whitney 151 
(U) test. 152 
 153 
Chemotaxis assay 154 
Cell migration was assessed using a 48-well Boyden microchamber (Neuro Probe, Cabin 155 
John, MD) as described previously (Gouwy et al., 2008). In brief, immature and mature 156 
MDDC were collected from the dishes by pipetting up and down. PBS was added to each dish 157 
and the dishes were incubated for 10 min at 4 °C to detach cells. The cells were centrifuged 158 
and resuspended in chemotaxis buffer [i.e. Hanks’ balanced salt solution (Invitrogen) 159 
supplemented with 1 mg/ml human serum albumin (Belgian Red Cross, Leuven, Belgium)]. 160 
Different concentrations of chemotactic factors were applied in wells of the lower 161 
compartment of the chamber and immature/mature MDDC (1x106 cells/ml) were added in the 162 
wells of the upper compartment. The lower and upper compartments were separated by a 5-163 
µm pore-size polyvinyl pyrrolidone membrane (GE Osmonics, Minnetonka, MN). After 164 
incubation at 37 °C for 1.5 h in humidified air with 5% CO2, the filters were removed and 165 
stained, and the cells migrated across the filter were counted microscopically (500x 166 
magnification). The results were presented as the chemotactic index (CI) calculated by 167 
dividing the number of migrated cells to the chemokine dilution through the number of cells 168 
that migrated spontaneously to the chemotaxis buffer. A chemotactic index ≥ 2 is considered 169 
to indicate that a chemotactic response to the tested chemokine was observed. Synergy 170 
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experiments were performed by adding two different chemokines together to the lower wells 171 
of the chamber. To study the effect of protein kinase inhibitors on the synergistic effect, 172 
immature MDDC were pretreated for 30 min with PD98059 (an ERK1/2 inhibitor; Merck 173 
Millipore, Overijse, Belgium) and wortmannin (a phosphatidylinositol-3-kinase inhibitor/Akt; 174 
Sigma) and loaded in the upper wells of the Boyden chamber. Statistically significant 175 
differences in CI between the combination of two chemokines and the sum of the indices 176 
obtained for the chemokines alone, as determined by the Mann-Whitney (U) test, are 177 
indicated by an asterisk (* p<0.05, **p<0.01). 178 
 179 
Signal transduction assay 180 
Immature MDDC were suspended at a concentration of 6x106 cells/ml (100 µl/tube) and 181 
incubated for 30 min at room temperature in serum-free starvation medium (RPMI medium 182 
without FCS) supplemented with 0.5 g/100 ml bovine serum albumin (BSA, Sigma). After 183 
starvation, cells were stimulated at 37 °C with chemokine or a combination of chemokines 184 
(diluted in 10 µl starvation medium + 0.5% BSA) in the presence or absence of ERK1/2 or 185 
Akt inhibitors. After 5 and 30 min, signal transduction was stopped by adding ice-cold PBS. 186 
Afterwards, cells were centrifuged and cell lysis (100 µl lysis buffer/sample) was performed 187 
in PBS containing 1 mM EDTA, 0.5 % Triton X-100, 5 mM NaF, 6 M urea, protease inhibitor 188 
cocktail for mammalian tissues and phosphatase inhibitor cocktails 1 and 2 (Sigma). The 189 
lysate was incubated for 45 min on ice and clarified (10 min, 1200g). The protein 190 
concentration in the supernatant was determined by the bicinchoninic acid (BCA) protein 191 
assay (Pierce, Rockford, IL). The amount of phosphorylated ERK1/2, Akt and p38 MAPK in 192 
the supernatant (picograms of phospho-kinase per mg of total protein) was determined using 193 
an ELISA for phospho-ERK1 (Thr202/Tyr204) plus phospho-ERK2 (Thr185/Tyr187), 194 
9 
 
phospho-Akt (S473) and phospho-p38α (T180/Y182) (R&D Systems). The ratio of phospho-195 
ERK, phospho-Akt and phospho-p38 MAPK to total protein content was calculated for cell 196 
lysates. Then, the results are expressed relative to the phosphorylation status of ERK, Akt and 197 
p38 MAPK after control treatment. Thus, 100% corresponds to the amount of phosphorylated 198 
ERK, Akt and p38 MAPK in medium-treated cells. Statistically significant differences in 199 
kinase phosphorylation between the combination of CCL3 and CXCL12 or fMLP and the sum 200 
of the kinase phosphorylation induced by the chemoattractants alone, determined by the Sign 201 
test, are indicated by asterisks (*p<0.05). 202 
 203 
Results 204 
Expression levels of markers and chemokine receptors on CD14+ monocytes, immature 205 
and mature MDDC 206 
Immature monocyte-derived DCs (MDDC) used for migration assays were generated by 207 
culturing human peripheral blood CD14+ monocytes for 6 days in medium supplemented with 208 
GM-CSF and IL-4, as evidenced (Table 1) by the significant decrease in CD14 expression 209 
(from 98.8±0.2 to 9.9±2.6% positive cells; n=6 and 15; p=0.0005) and a drastic increase in the 210 
cell surface markers DC-SIGN (from 0.1±0.1 to 88.6±3.6%; n=9 and 19; p=0.0006) and 211 
CD1a (from 0.1±0.1 to 72.2±3.5%; n=5 and 12; p=0.0007). Such immature MDDC expressed 212 
chemokine receptors with an increase for CCR1 (to 61.4±8.7% positive cells), CCR5 (to 213 
50.2±7.2%), CXCR1 (to 33.7±13.0%) and CXCR2 (to 25.5±0.4%), but a decrease in CCR2 ( 214 
to 26.3±4.7%) compared to CD14+ monocytes. After a further 48 h incubation with LPS, the 215 
expression level of the DC maturation markers CD80 (83.3±9.5% positive cells; n=7; 216 
p=0.026), CD83 (60.2±9.4%; n=9; p=0.0006) and the chemokine receptors CXCR4 217 
(19.3±4.6%; n=10; p=0.04) and CCR7 (45.0±6.9%; n=10; p=0.003) were significantly 218 
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upregulated compared to immature MDDC, whereas CCR1 (18.0±7.0%; n=9; p=0.004), 219 
CCR2 (10.1±4.0%; n=9; p=0.01) and CCR5 (20.5±4.6%; n=9; p=0.006) expression was 220 
significantly reduced on mature MDDC compared to immature MDDC (Table 1 and Fig. 1).  221 
The % CD86 positive cells was the same for the population of immature and mature MDDC, 222 
but the mean fluorescence intensity (MFI) of CD86 on mature MDDC was higher than on 223 
immature MDDC, suggesting a higher receptor density per cell (data not shown). 224 
 225 
Synergy between CC and CXC chemokines in immature MDDC chemotaxis 226 
Recently, we found that the CC chemokine CCL5 synergistically cooperates with the 227 
homeostatic CXC chemokine CXCL12 in monocyte migration via binding to CCR1 and 228 
CXCR4, respectively (Gouwy et al., 2011). Similarly, to assess whether the CCR1 and CCR5 229 
ligand CCL3 was able to synergize with the CXCR4 ligand CXCL12 in immature MDDC 230 
chemotaxis, different concentrations of CCL3 and CXCL12 were added together in the lower 231 
compartment of the Boyden microchamber for chemotaxis. CCL3 alone showed a dose-232 
response curve reaching a chemotactic index as high as 17.6±2.9 (CI±SEM) at 0.1 ng/ml, 233 
which was much higher than that of CXCL12 (Fig. 2). This finding fits with the high (≥ 50% 234 
positive cells) CCR1 and CCR5 versus low (< 10% positive cells) CXCR4 expression levels 235 
on immature MDDC (Table 1 and Fig. 1). Moreover, when CCL3 (0.03 ng/ml) was added 236 
together with different concentrations of CXCL12 (30, 100 and 300 ng/ml), the number of 237 
migrating immature MDDC was significantly increased above the sum of migrated cells 238 
obtained with the individual chemokines (Fig. 3A). In a similar experimental setting, another 239 
CXC chemokine, i.e. the CXCR1,2 agonist CXCL8 was verified for its cooperative effect 240 
with CCL3 in immature MDDC chemotaxis. CXCL8 (10 ng/ml) alone was found to 241 
significantly (p=0.02) chemoattract immature MDDC (CI±SEM of 4.7±1.8 at 10 ng/ml) 242 
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which is in line with the enhanced CXCR1 and CXCR2 expression (≥ 25% positive cells) 243 
compared to CD14+ monocytes (Fig. 3B and Table 1). Furthermore, CXCL8 (10 ng/ml) 244 
significantly augmented the migration of immature MDDC to CCL3 (0.1 ng/ml) in the 245 
chemotaxis assay (p=0.02) (Fig. 3B). Finally, Fig. 3C shows that synergy between the CCR2 246 
ligand CCL2 (300 ng/ml) and CXCL12 (30, 100 and 300 ng/ml) to chemoattract immature 247 
MDDC could only be reached at high concentrations of both ligands (Fig. 3C). A previous 248 
study demonstrated that CCL2 and CXCL12 synergized to chemoattract CD14+ monocytes in 249 
the Boyden microchamber assay (Gouwy et al., 2008) at much lower concentrations (0.3 and 250 
1 ng/ml) of CCL2 which is in line with the higher CCR2 expression levels on CD14+ 251 
monocytes (51.6±14.2 versus 26.3±4.7% positive cells) (Table 1 and Fig. 1). These data 252 
indicate the importance of chemokine receptor expression levels on the target cells which 253 
correlate with the synergistic interaction capacity between chemokines in the migration of 254 
leukocytes. Indeed, also lower concentrations of CXCL8 (10 ng/ml) were found to synergize 255 
with CCL3 in immature MDDC migration (Fig. 3B) compared to higher concentrations of 256 
CXCL8 (100 ng/ml) needed to reach synergy in CD14+ monocyte migration (Gouwy et al., 257 
2008).  258 
Synergy between two CXC chemokines in immature MDDC migration 259 
As evidenced above, a combination of CC and CXC chemokines signaling via unrelated 260 
receptors is providing a good chance to observe synergistic interactions. In a further attempt 261 
to precisely delineate the spectrum of synergy between chemokines for immature MDDC 262 
chemotaxis, the CXC chemokines CXCL8 and CXCL12 were combined on immature MDDC 263 
in the Boyden microchamber assay (Fig. 4). The CXCR1/CXCR2 agonist CXCL8 and the 264 
CXCR4 agonist CXCL12 alone at 30 ng/ml showed detectable immature MDDC chemotactic 265 
activity, with an index of 8.1±1.4 (CI±SEM) and 2.2±0.8, respectively. Further, CXCL8 (10 266 
or 30 ng/ml) significantly (p=0.037 and p=0.001, respectively) increased the chemotactic 267 
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response of immature MDDC toward 30 or 100 ng/ml CXCL12 (Fig. 4A). For example, the 268 
chemotactic index reached at 10 ng/ml of CXCL8 (6.9±1.6) and at 30 ng/ml of CXCL12 269 
(2.2±1.0) was significantly (p=0.037) increased to 13.9±2.1 if these chemokines were 270 
combined. This is surprising since these two CXC chemokines did not synergize in monocytic 271 
cell chemotaxis (Gouwy et al., 2008). The lower expression levels of CXCR1 on monocytic 272 
cells compared to immature MDDC (5.8±5.8% versus 33.7±13% positive cells) might explain 273 
this difference. Alternatively, two CC chemokines attracting immature MDDC i.e. CCL7 (30 274 
and 300 ng/ml) and CCL3 (0.1 and 0.3 ng/ml), sharing CCR1 as common upregulated 275 
receptor in immature MDDC, were not able to synergize in the Boyden microchamber assay 276 
when tested at various concentrations (Fig. 4B). Indeed, only a cumulative effect was 277 
observed when CCL7 and CCL3 were combined. These data indicate that chemokines 278 
competing for the same receptor do probably not synergize for chemotaxis.  279 
 280 
Synergy between CC and CXC chemokines in mature MDDC chemotaxis 281 
During dendritic cell maturation, the expression level of the chemokine receptors CXCR4 and 282 
CCR7 were significantly (p=0.045 and p=0.003, respectively) upregulated (from 7.5±2.4 to 283 
19.3±4.6 and from 15.7±1.9 to 45.0±6.9 % positive cells, respectively) (Table 1 and Fig. 1). 284 
We therefore evaluated the combination of different concentrations of their ligands CXCL12 285 
(100 and 300 ng/ml) and CCL21 (10 and 30 ng/ml) to measure mature DC migration in the 286 
Boyden chemotaxis assay (Fig. 5A). The CCR7 agonist CCL21 alone had significant 287 
chemotactic activity for mature MDDC (CI±SEM of 6.0±1.5 at 10 ng/ml), whereas CXCL12 288 
was only weakly active (CI±SEM of 1.6±0.4 at 1 µg/ml). However, significant synergy was 289 
observed when CXCL12 (100 and 300 ng/ml) was combined with different concentrations of 290 
CCL21 (10 and 30 ng/ml) (Fig. 5A). For example, the chemotactic index reached at 10 ng/ml 291 
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of CCL21 (6.0±1.5) and at 300 ng/ml of CXCL12 (1.1±0.5) was significantly (p=0.049) 292 
increased to 18.9±2.1 if these chemokines were combined (Fig. 5A). In contrast, mature 293 
MDDC with lowered CCR1 and CCR5 expression (≤ 20% positive cells) compared to 294 
immature MDDC, did not migrate to CCL3 and CCL3 did not cooperate with CXCL12 in 295 
mature MDDC chemotaxis (Fig. 5B). The chemotactic migratory responses to inflammatory 296 
chemokines such as CCL3 were previously reported to be significantly decreased after 297 
differentiation of immature MDDC into mature MDDC (Sozzani et al., 1999). 298 
 299 
Synergy between CC chemokines and non-chemokine GPCR-binding inflammatory 300 
mediators in immature MDDC chemotaxis and signaling 301 
Chemerin is a chemotactic protein identified as the natural ligand of ChemR23, a G protein-302 
coupled receptor expressed by immature MDDC (Bondue et al., 2011; Samson et al., 1998). 303 
To verify whether chemerin directly cooperates with CCL7 on immature MDDC, chemerin 304 
was added together with CCL7 in the lower compartment of the Boyden microchamber (Fig. 305 
6A). Although chemerin is a weaker immature MDDC chemoattractant, e.g. CI±SEM of 306 
3.5±1.5 at 1000 ng/ml, than CCL7, its chemotactic effect confirms the expression of 307 
functional chemerin receptors on immature MDDC (Samson et al., 1998; Bondue et al., 308 
2011). Moreover, the combination of chemerin (1000 ng/ml) and CCL7 (300 ng/ml) caused a 309 
statistically significant (i.e., CI±SEM of 28.6±2.9, p=0.009) increase above the additive 310 
immature MDDC response obtained with CCL7 and chemerin alone (CI±SEM of 14.2±1.6 311 
and 3.5±1.5, respectively). This demonstrates that the GPCR ligand chemerin and the 312 
chemokine CCL7, although binding to unrelated GPCRs, can synergize in immature MDDC 313 
chemotaxis (Fig. 6A). In addition, the combination of the non-chemokine GPCR ligand fMLP 314 
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(10-8 M) and CCL3 (0.1 ng/ml) also caused a statistically significant (p=0.049) increase above 315 
the additive MDDC response obtained with fMLP and CCL3 alone (Fig. 6B).  316 
Activation of GPCRs does not just lead to signaling via a single pathway, but rather triggers 317 
several separate coinciding signals within the same cell. Interaction between these different 318 
GPCR signal transduction pathways may result in increased cellular responses. Chemokine 319 
amplification of inflammatory responses in leukocytes could be mediated through the 320 
synergistic interplay of distinct signaling pathways downstream of GPCR activation (Gouwy 321 
et al., 2005). To determine which signaling pathways might mediate the synergy between 322 
CCL3 and fMLP in immature MDDC chemotaxis, we stimulated cells with CCL3 (0.3 or 1 323 
ng/ml), fMLP (10-9 M) or a combination of CCL3 and fMLP for 5 min and performed ELISA 324 
for phospho-ERK1/2 and phospho-Akt on the cell lysates. Figure 6C shows that immature 325 
MDDC incubated for 5 min with fMLP (10-9 M) or CCL3 (1 ng/ml) contained higher levels of 326 
phosphorylated ERK1/2 and Akt protein compared to buffer-treated cells. Furthermore, 327 
synergy between fMLP and CCL3 was observed in ERK1/2 and Akt phosphorylation 328 
(p=0.013 and p=0.013, respectively) in agreement with the fact that CCL3 synergizes with 329 
fMLP in immature MDDC migration (Fig. 6B). 330 
 331 
CC and CXC chemokines cooperate in immature MDDC chemotaxis via Akt and 332 
ERK1/2 signaling   333 
Next, we examined the involvement of the ERK1/2, Akt and p38 MAPK pathway in the 334 
synergistic effect between CCL3 and CXCL12 on immature MDDC. Figure 7A shows that in 335 
immature MDDC incubated for 5 min with CCL3 or CXCL12 significant phosphorylation of 336 
ERK1/2 protein was induced compared with buffer-treated cells (p=0.008 and p=0.0004, 337 
respectively). Furthermore, when immature MDDC were incubated for 5 min with a 338 
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combination of 0.3 ng/ml of CCL3 and 100 ng/ml of CXCL12, cooperation was observed in 339 
ERK1/2 phosphorylation compared with the sum of ERK phosphorylation by CCL3 and 340 
CXCL12 alone (p=0.02). This is in agreement with the fact that CCL3 synergizes with 341 
CXCL12 in immature MDDC migration (Fig. 3A). When the immature MDDC were 342 
incubated during 30 min with a combination of CCL3 and CXCL12, no significant 343 
enhancement in ERK phosphorylation was observed (Fig. 7A). Next, we investigated whether 344 
a combination of CCL3 (0.3 ng/ml) and CXCL12 (100 ng/ml) could enhance Akt 345 
phosphorylation in immature MDDC. CCL3 and CXCL12 induced significant Akt 346 
phosphorylation within 5 min in immature MDDC compared to buffer-treated cells (p=0.02 347 
and p=0.005, respectively), but no synergistic effect was observed. However, the combination 348 
of CCL3 and CXCL12 cooperatively (p=0.004) induced a sustained Akt phosphorylation that 349 
could still be observed after 30 min of stimulation, a time period after which the effect of the 350 
individual chemokines was less pronounced (Fig. 7B). In contrast, no significant increase in 351 
p38 MAPK phosphorylation was detected after 5 or 30 min of stimulation of immature 352 
MDDC with CXCL12 (100 ng/ml), whereas CCL3 (1 ng/ml) induced significant (p=0.001) 353 
p38 MAPK phosphorylation within 5 min in immature MDDC compared to buffer-treated 354 
cells. Moreover, CCL3 and CXCL12 did not cooperate to enhance the phosphorylation of p38 355 
MAPK in immature MDDC at both time points tested (Fig. 7C). Incubation of immature 356 
MDDC with the CXCR4 antagonist AMD3100 (10 µg/ml) did block the CXCL12 (100 357 
ng/ml) induced phosphorylation of Akt after 30 min. Moreover, no cooperation was observed 358 
between CXCL12 (100 ng/ml) and CCL3 (0.1 ng/ml) in Akt phosphorylation in the presence 359 
of AMD3100 (Fig. 7D). 360 
 361 
 362 
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The effect of protein kinase inhibitors on the synergistic effect between CCL3 and 363 
CXCL12 in immature MDDC chemotaxis 364 
To determine whether the Akt and ERK1/2 pathway mediate the synergistic effect between 365 
CCL3 and CXCL12 on immature MDDC chemotaxis, MDDC were treated with their 366 
corresponding inhibitors PD98059 or wortmannin before transfer to the upper wells of the 367 
Boyden chamber. Figure 8 illustrates that the chemotactic response to CCL3 (0.03 ng/ml) or 368 
CCL3 (0.03 ng/ml) in combination with CXCL12 (300 ng/ml) was not inhibited by PD98059. 369 
Nevertheless, a significant inhibition of the chemotactic response to CCL3 (0.03 ng/ml) and 370 
the synergy between CCL3 (0.03 ng/ml) and CXCL12 (300 ng/ml) was observed with 371 
wortmannin (100 nM). The inhibitory capacity of the PD98059 preparation was confirmed in 372 
the signaling assay. Both PD98059 (50 µM) and wortmannin (100 nM) inhibited the CCL3 373 
(0.1 ng/ml) induced phosphorylation of ERK1/2 and Akt, respectively (data not shown). We 374 
can therefore conclude that chemotaxis of immature MDDC either induced by CCL3 as a 375 
single stimulus or in combination with CXCL12 is independent of the ERK1/2 pathway. 376 
 377 
Discussion  378 
Immature MDDC express a unique repertoire of inflammatory chemokine receptors (e.g. 379 
CCR1, CCR2, CCR5, CXCR1 and CXCR2), which bind a pattern of inflammatory 380 
chemokines, including CCL2, CCL3, CCL7 and CXCL8. Dendritic cells reside in an 381 
immature state in peripheral blood or tissues where they are activated by inflammatory 382 
cytokines or antigens. After activation DC traffic via the afferent lymphatics into the draining 383 
lymph node to initiate immune responses. A dramatic change in the repertoire of chemokine 384 
receptors occurs during DC activation and maturation. Inflammatory chemokine receptors are 385 
down-regulated whereas the expression of CCR7, the receptor for CCL19 and CCL21, two 386 
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chemokines which are expressed at the luminal side of high endothelial cells and in the T cell 387 
rich areas of lymph nodes, is upregulated. This change in chemokine receptor repertoire is 388 
responsible for the migration of DC from the periphery to the draining lymph nodes (Caux et 389 
al., 2000). Simultaneously, the up-regulated cell surface receptors which act as co-receptors in 390 
T-cell activation, such as CD80 and CD83, enhance their ability to activate T cells (Lin et al., 391 
1998; Sallusto et al., 1998; Sozzani S, 2005). 392 
Here, we show that CXCL8 and CXCL12 significantly increase the chemotactic response of 393 
immature MDDC toward low concentrations of the CC chemokine CCL3 (Fig. 3). The 394 
chemotactic responses to the inflammatory chemokines CXCL8 and CCL3 were increased 395 
after transition of CD14+ monocytes into immature MDDC, which is in line with the higher 396 
CCR1, CCR5, CXCR1 and CXCR2 expression on immature MDDC compared to CD14+ 397 
monocytes (Table 1 and Fig. 1). For synergy between CXCL12 and CCL2 rather high 398 
concentrations (300 ng/ml) of the latter were required, which corresponds with reduced CCR2 399 
expression on immature MDDC compared to monocytes (Fig. 3C and Table 1). Moreover, 400 
two CXC chemokines not sharing receptors (i.e. CXCL8 and CXCL12) also synergized in 401 
immature MDDC chemotaxis (Fig. 4A). In contrast, the combination of two CC chemokines 402 
(i.e. CCL3 and CCL7) did not provide synergy in immature MDDC chemotaxis (Fig. 4B). 403 
These latter data could implicate that chemokines competing for the same receptor (i.e. 404 
CCR1) do not synergize for chemotaxis. Interaction between CXC chemokines in 405 
plasmacytoid DC migration has been described in other studies (Krug et al., 2002; 406 
Vanbervliet et al., 2003). The cooperation between inducible CXCR3 ligands and constitutive 407 
CXCL12 may regulate recruitment of plasmacytoid DC either to lymph nodes or to peripheral 408 
sites of inflammation (Vanbervliet et al., 2003). In contrast to these plasmacytoid DC, the 409 
immature MDDC described here show only a low CXCR3 expression (7.9±1.9% positive 410 
cells; n=6). 411 
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Alternatively, we found that CCL3 was not active and did not cooperate with CXCL12 in 412 
mature MDDC chemotaxis (Fig. 5B), whereas CCL3 synergized with CXCL12 in immature 413 
MDDC chemotaxis (Fig. 3A). MDDC maturation is accompagnied by functional upregulation 414 
of CCR7 and is associated with down-regulation of receptors for inflammatory chemokines 415 
(e.g. CCR1/CCR5), hampering CCL3 chemotaxis and thereby explaining why CCL3 is not 416 
able to cooperate with CXCL12 in mature MDDC chemotaxis. Further, it appears that most of 417 
the inflammatory chemokine receptors expressed by these mature MDDC (e.g. CCR1/CCR5) 418 
are not functional, whereas these receptors were operational on immature MDDC (Sallusto et 419 
al., 1998). In an inflammatory environment, IL-10 causes in DC uncoupling of functional 420 
receptors, which act as molecular sinks and scavengers for inflammatory chemokines 421 
(D’amico et al., 2000). Indeed, DCs treated with LPS and IL-10 showed little or no migration 422 
in response to CCL3, despite high expression levels of CCR1 and CCR5. Coupling of 423 
chemokine receptors to chemotaxis is also regulated at the receptor signaling level (D’amico 424 
et al., 2000; Sato et al., 2001). Thus, failure of CCL3 and CXCL12 to synergize in mature 425 
MDDC chemotaxis can be the consequence of receptor down-regulation and/or receptor 426 
uncoupling on these cells (Lin et al., 1998). Along the same line, mature MDDC express 427 
CXCR4, but only marginally migrate in response to constitutive CXCL12. Earlier studies 428 
have shown indeed that blood DC maturated in vitro apparently do not express functional 429 
CXCR4 due to auto-desensitization of CXCR4 during maturation (Sallusto et al., 1998). 430 
Similarly, Penna et al. demonstrated equal chemokine expression but distinct migration 431 
patterns for blood myeloid DCs and plasmacytoid DCs (Penna et al., 2001). Moreover, 432 
Humrich et al. described that, although CCR7 and CXCR4 were expressed at a similar level 433 
on mature MDDC, CCL19 and CCL21 induced a more potent chemotactic response in mature 434 
DC compared to CXCL12 (Fig. 5A) (Humrich et al., 2005). In the present study we observed 435 
that at different concentrations, CXCL12 significantly elevated CCL21-induced mature 436 
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MDDC chemotaxis, indicating that the enhanced expression of CXCR4 on mature MDDC is 437 
at least in part functional for migration. A conceivable explanation for its function on mature 438 
MDDC is that CXCL12 is synergizing with CCR7 ligands to drive migration in the lymph 439 
node to the site of T cell priming. Recent reports described cooperation between CCL21 and 440 
CXCL12 in T lymphocyte and plasmacytoid DC migration (Bai et al., 2009; Umemoto et al., 441 
2012).  442 
Furthermore, we report here that chemerin, the natural ligand of the GPCR ChemR23, was 443 
able to cooperate with CCL7 in immature MDDC chemotaxis (Fig. 6A). ChemR23 is a 444 
chemoattractant receptor relatively specific for antigen-presenting cells and it plays an 445 
important role in the recruitment or trafficking of macrophages and dendritic cells (Samson et 446 
al., 1998). The binding of chemerin to ChemR23, which is expressed on immature MDDC, is 447 
important for synergy with CCL7 in chemotaxis. The non-chemokine GPCR ligand fMLP 448 
also synergized with CCL3 in immature MDDC chemotaxis (Fig. 6B) and signaling (Fig. 6C). 449 
Fillion et al. described a role of chemokines and formyl peptides in pneumococcal 450 
pneumonia-induced monocyte/macrophage recruitment (Fillion et al., 2001). It is documented 451 
that immature DCs express functional receptors (i.e. FPR, FPRL1 and FPRL2) for formylated 452 
peptides (Sozzani S, 2005; Yang et al., 2000). The phenomenon of synergy between 453 
chemokines and other GPCR ligands is controlled by multiple parameters, including (1) target 454 
cell (different sensitivity to chemokines depending on cell type and receptor expression), (2) 455 
kinetics of production, (3) dose (for each combination a different and narrow optimal in vitro 456 
concentration range is required for each ligand, which will not necessarily reflect the optimal 457 
dose in vivo) and (4) site of secretion (chemokines develop a gradient in vivo and some may 458 
be quickly inactivated by NH2-terminal cleavage depending on the presence of proteases). 459 
 It seems there is still much to uncover on the molecular mechanisms involved in the synergy 460 
between chemokines. Experimental evidence with leukocytes has nevertheless shown that 461 
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after engangement of multiple chemokine receptors not only cell migration is cooperatively 462 
affected but also that intracellular signaling is enhanced (Gouwy et al., 2008; Gouwy et al., 463 
2011, Mellado et al., 2001; Sebastiani et al., 2005). In this report we found that CXCL12 and 464 
CCL3 cooperated in ERK1/2 and Akt phosphorylation and this synergy in signaling is 465 
inhibited by the CXCR4 antagonist AMD3100 (Fig. 7D). The kinetics of synergy between 466 
this CC and CXC chemokine in ERK1/2 phosphorylation was different compared to Akt 467 
activation. Thus, synergy between chemokines in leukocyte migration requires the 468 
coordination or cross-talk between several signal transduction cascades (Kuscher et al., 2009; 469 
Mellado et al., 2001; Sebastiani et al., 2005; Vanbervliet et al., 2003). Indeed, several studies 470 
showed that multiple intracellular signaling pathways are simultaneously activated by a 471 
combination of chemokines. However, we report here that in all probability, the Akt pathway 472 
is a major pathway mediating the synergy between CCL3 and CXCL12 in immature MDDC 473 
chemotaxis (Fig. 8). Additional mechanisms for chemokine synergism, e.g. involving a single 474 
chemokine receptor triggered by its agonist heterodimerized to a synergy-inducing 475 
chemokine, have been proposed (Kuscher et al., 2009; Sebastiani et al., 2005). Alternatively, 476 
receptor heterodimerization has been reported to explain synergism (Mellado et al., 2001). 477 
In summary, our study documents the synergy between CC and CXC chemokines in 478 
immature MDDC chemotaxis and provides evidence for the molecular mechanisms 479 
underlying this action. Furthermore, our results show that the synergy among different 480 
chemotactic receptors represent a more widespread mechanism that encompasses chemokine 481 
receptors, classic chemotactic receptors (ChemR23) and formyl peptide receptors (FPR). This 482 
suggests that inflammatory chemotactic receptors act in concert to promote the localization of 483 
immature MDDC to inflamed peripheral non-lymphoid tissues. Antigen induced maturation 484 
will subsequently cause the loss of DC responsiveness to the locally produced chemotactic 485 
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factors favoring the CCR7-dependent migration of maturing DC to secondary lymphoid 486 
organs in response to the synergistic action of CCR7 and CXCR4 ligands. 487 
 488 
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Figure Legends 639 
Figure 1: The expression of chemokine receptors on CD14+ monocytes, immature and 640 
mature MDDC 641 
FACS analysis showing chemokine receptor expression on CD14+ monocytes, immature 642 
(iMDDC) and mature MDDC (mMDDC) was performed as described in Materials and 643 
Methods. One experiment representative out of 10 is shown. The shaded histograms represent 644 
the staining by the chemokine-receptor specific antibody. The open histograms represent the 645 
background staining.  Numbers in the histograms indicate the mean fluorescence intensity 646 
(MFI). The shaded histograms show that positive cells for a certain chemokine receptor 647 
represent a single cell population. 648 
 649 
Figure 2: Dose response curve of CC and CXC chemokines on immature MDDC 650 
CCL2, CCL3, CCL7, CXCL8 and CXCL12 were evaluated for chemotactic activity on 651 
immature MDDC in the Boyden microchamber chemotaxis assay. The chemotactic activities 652 
are expressed as chemotactic indexes (CI) and the results represent the mean CI ± SEM from 653 
4 to 7 independent experiments. †, p<0.05, ‡, p<0.01, statistically significant induced 654 
chemotaxis compared with buffer, as determined by the Mann-Whitney U test. 655 
 656 
Figure 3: Synergy between CC and CXC chemokines in immature MDDC chemotaxis 657 
Panel A and B: CCL3 (0.03 for panel A; 0.1 for panel B) was added together with CXCL12 658 
(30 to 300 ng/ml for panel A) or CXCL8 (10 to 100 ng/ml for panel B) in the lower 659 
compartment of the Boyden microchamber to measure immature MDDC chemotaxis. Panel 660 
29 
 
C: CXCL12 (30 to 300 ng/ml) was combined with CCL2 (300 ng/ml) in the lower 661 
compartment of the Boyden microchamber to measure immature MDDC chemotaxis. The CI 662 
is expressed as the mean ± SEM, derived from 4 to 6 independent experiments. *p<0.05, 663 
**p<0.01, statistically significant differences in chemotactic indices between the combination 664 
of two chemokines and the sum of the indices obtained for the chemokines alone, as 665 
determined by the Mann-Whitney U test. †, p<0.05, ‡, p<0.01, statistically significant induced 666 
chemotaxis compared with buffer, as determined by the Mann-Whitney U test. 667 
 668 
Figure 4: Synergy between two CXC chemokines in immature MDDC chemotaxis 669 
CXCL8 (10 and 30 ng/ml) was added together with CXCL12 (30 and 100 ng/ml) (panel A) 670 
and CCL3 (0.1 and 0.3 ng/ml) was combined with CCL7 (30 and 300 ng/ml) (panel B) in the 671 
lower compartment of the microchamber to measure immature MDDC chemotaxis. The CI is 672 
expressed as the mean, derived from 5 to 7 independent experiments. *p<0.05, **p<0.01, 673 
statistically significant differences in chemotactic indices between the combination of two 674 
chemokines and the sum of the indices obtained for the chemokines alone, as determined by 675 
the Mann-Whitney U test. †, p<0.05, ‡, p<0.01, statistically significant induced chemotaxis 676 
compared with buffer, as determined by the Mann-Whitney U test. 677 
 678 
Figure 5: Synergy between CC and CXC chemokines in mature MDDC chemotaxis 679 
CCL21 (10 and 30 ng/ml) or CCL3 (3 and 30 ng/ml) were combined with CXCL12 (100 and 680 
300 ng/ml) in the lower compartment of the microchamber to measure mature MDDC 681 
chemotaxis. The CI is expressed as the mean, derived from 3 to 4 independent experiments. 682 
*p<0.05, statistically significant differences in chemotactic indices between the combination 683 
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of two chemokines and the sum of the indices obtained for the chemokines alone, as 684 
determined by the Mann-Whitney U test. †, p<0.05, statistically significant induced 685 
chemotaxis compared with buffer, as determined by the Mann-Whitney U test. 686 
 687 
Figure 6: Synergy between CC chemokines and non-chemokine GPCR-binding 688 
inflammatory mediators in immature MDDC chemotaxis and signaling 689 
Panel A: CCL7 (30 and 300 ng/ml) was added together with chemerin (100 and 1000 ng/ml) 690 
in the lower compartment of the microchamber to measure immature MDDC chemotaxis. 691 
Panel B: CCL3 (0.03 and 0.1 ng/ml) was added simultaneously with the bacterial peptide 692 
fMLP (10-8 M and 10 -9 M) in the lower compartment of the microchamber to measure 693 
immature MDDC chemotaxis. The CI is expressed as the mean, derived from 2 to 5 694 
independent experiments. *p<0.05; **p<0.01 statistically significant differences in 695 
chemotactic indices between the combination of two chemoattractants and the sum of the 696 
indices obtained for the chemoattractants alone, as determined by the Mann-Whitney U test. 697 
†, p<0.05, ‡, p<0.01, statistically significant induced chemotaxis compared with buffer, as 698 
determined by the Mann-Whitney U test. Panel C: Immature MDDC were stimulated with 699 
CCL3 (1 ng/ml), fMLP (10 -9 M) or a combination of CCL3 and fMLP. The amount of 700 
phosphorylated ERK1/2 and Akt in the cell lysates was determined by ELISA. The mean 701 
values ± SEM are derived from 7 to 8 independent experiments. 100% phosporylation 702 
corresponds to the amount of phosphorylated Akt and ERK1/2 in medium-treated cells. 703 
Statistically significant kinase phosphorylation induced by CCL3 or fMLP compared with 704 
medium-treated cells († p<0.05) and cooperation in signaling between CCL3 and fMLP (* 705 
p<0.05) was determined by the Mann-Whitney U test and Sign test, respectively. 706 
 707 
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Figure 7: CC and CXC chemokines cooperate in immature MDDC via Akt and ERK1/2 708 
signaling  709 
Immature MDDC were stimulated with CCL3 (0.3 for panel A and B; 1 ng/ml for panel C; 710 
0.1 ng/ml for panel D), CXCL12 (100 ng/ml) or a combination of CCL3 and CXCL12 for 5 711 
(panel A-C) or 30 min (panel A-D). In panel C immature MDDC were treated with 712 
AMD3100 (10 µg/ml) or vehicle control. The amount of phosphorylated ERK1/2, Akt and 713 
p38 MAPK in the cell lysates was determined by ELISA. The mean values ± SEM are derived 714 
from 6 to 12 independent experiments. 100% corresponds to the amount of phosphorylated 715 
Akt, ERK1/2 and p38 MAPK in medium-treated cells. Statistically significant kinase 716 
phosphorylation induced by CCL3 or CXCL12 compared with medium-treated cells († 717 
p<0.05, ‡ p<0.01) and cooperation in signaling between CCL3 and CXCL12 (* p<0.05, 718 
**p<0.01) was determined by the Mann-Whitney U test and Sign test, respectively. 719 
 720 
Figure 8: Effect of protein kinase inhibitors on the synergy between CCL3 and CXCL12 721 
in immature MDDC chemotaxis 722 
CCL3 (0.03 ng/ml) was added together with CXCL12 (300 ng/ml) in the lower compartment 723 
of the microchamber to measure immature MDDC chemotaxis. Cells were pretreated with 724 
chemotaxis buffer (control), PD98059 (50 µM) or wortmannin (100 nM) before loading to the 725 
Boyden chamber. The CI is expressed as the mean, derived from 6 to 8 independent 726 
experiments. Statistically significant inhibition of the chemotactic response († p<0.05) is 727 
determined by the Sign test.  728 
 729 
 730 
32 
 
Table 1: The expression of surface markers and chemokine receptors on CD14+ 731 
monocytes, immature MDDC and mature MDDC 732 
Percentage of chemokine receptor positive cellsa 733 
 734 
Percentage of cell surface markers positive cellsb 735 
 736 
PBMCs were isolated from blood derived buffy coats. CD14+ monocytes, isolated by MACS, were cultured with 737 
50 ng/ml GM-CSF and 20 ng/ml IL-4 for 6 days to generate immature MDDC (iMDDC). For maturation 738 
(mMDDC), dendritic cells were incubated for 48 h in medium containing 1 µg/ml LPS. Expression of several 739 
chemokine receptorsa and cell surface markersb was analyzed by flow cytometry with specific monoclonal 740 
antibodies. Data represent mean % positive cells ± SEM from 10 different donors. 741 
 742 
 
Cell type 
 
CCR1 
 
CCR2 
 
CCR5 
 
CXCR1 
 
CXCR2 
 
CXCR4 
 
CCR7 
Monocytes 48.1±15.3 51.6±14.2 19.8±8.7   5.8±5.8 9.8±2.8 4.4±3.4  4.6±1.4 
iMDDC  61.4±8.7 26.3±4.7 50.2±7.2 33.7±13   25.5±0.4 7.5±2.4 15.7±1.9 
mMDDC  18.0±7.0 10.1±4.0 20.5±4.6 16.4±6.4 7.0±3.7 19.3±4.6 45.0±6.9 
 
Cell type 
 
DC-SIGN 
 
CD1a 
 
CD11b 
 
CD14 
 
CD80 
 
CD83 
 
CD86 
Monocytes  0.1±0.1 0.1±0.1 84.0±4.0 98.8±0.2  0.0±0.0 4.8±1.3 98.4±0.2 
iMDDC 88.6±3.6 72.2±3.5 89.9±3.0  9.9±2.6 58.8±9.3 7.6±2.6 88.9±1.7 
mMDDC 78.6±4.7 74.4±5.5 88.8±4.5  18.9±10.7 83.3±9.5  60.2±9.4 93.0±2.2 
